[1] 张蔼玲， 李颖玉， 李永生，等. 血浆置换与血浆免疫吸附治疗神经系统自身免疫性疾病的疗效及安全性[j]. 临床医学工程，2015，22（8）：1032-1033.
[2] 贾立明，景永峰，武卫周，等. 血浆置换与血浆免疫吸附对神经系统自身免疫性疾病的疗效与不良反应分析[j]. 中国实用医药，2016，11（16）：12-13.
[3] Dorst J, Fangerau T, Taranu D, et al. Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial[j]. EClinicalMedicine, 2019, 16: 98-106.
[4] Oji S, Nomura K. Immunoadsorption in neurological disorders[j]. Transfus Apher Sci, 2017, 56(5): 671-676.
[5] Fernández-Zarzoso M, Gómez-Seguí I, de la Rubia J. Therapeutic plasma exchange: Review of current indications[j]. Transfus Apher Sci, 2019, 58(3): 247-253.
[6] Lu J, Zhang L, Xia C, et al. Complications of therapeutic plasma exchange: A retrospective study of 1201 procedures in 435 children [j]. Medicine (Baltimore), 2019, 98(50): e18308.
[7] Oji S, Nomura K. Immunoadsorption in neurological disorders[j]. Transfus Apher Sci
,2017, 56(5):671-676.
[8] Graus F, Titulaer MJ, Balu R ,et al. A clinical approach to diagnosis of autoimmune encephalitis[j]. Lancet Neurol, 2016, 15(4): 391-404.
[9] Shin Y, Lee S, Park K, et al. Treatment strategies for autoimmune encephalitis [j]. Ther Adv Neurol Disord, 2017, 11: 175-194.
[10] Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study[j]. Lancet Neurol, 2013, 12(2):157-165.
[11] DeSena AD, Noland DK, Matevosyan K, et al. Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-N-methyl-D-aspartate receptor antibody encephalitis: A retrospective review[j]. J Clin Apher, 2015 , 30(4):212-216.
[12] Heine J, Ly LT,Lieker I, et al. Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study[j]. J Neurol,2016, 263(12): 2395-2402.
[13] Dorst J,Fangerau T, Taranu D, et al. Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial[j]. E Clinical Medicine, 2019, 16:98-106.
[14] Song W, Qu Y, Huang X. Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders[j]. Int Ophthalmol, 2019 , 39(11): 2477-2483.
[15] Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue[j]. J Clin Apher, 2019, 34(3):171-354.
[16] Lipphardt M, Mühlhausen J, Kitze B, et al. Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica[j]. J Clin Apher, 2019, 34(4):381-391.
[17] Hiew F, Ramlan R, Viswanathan S, et al. Guillain-Barré Syndrome, variants & forms fruste: Reclassification with new criteria [j]. Clin Neurol Neurosurg, 2017, 158: 114-118.
[18] Taams N, Notermans N, Fokkink W, et al. Clinical relevance of serum antibodies to GQ1b in immune-mediated neuropathies [j]. J Peripher Nerv Syst, 2018, 23(4): 227-234.
[19] Ito M, Kuwabara S, Odaka M, et al. Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases[j]. J Neurol, 2008 , 255(5):674-682.
[20] Chevret S, Hughes R, Annane D, et al. Plasma exchange for Guillain-Barré syndrome[j]. Cochrane Database Syst Rev, 2017, 2(2):CD001798.
[21] Dorst J, Fillies F, Dreyhaupt J, et al. Safety and tolerability of plasma exchange and immunoadsorption in neuroinflammatory diseases [j]. J Clin Med, 2020, 9(9): E2874.
[22] Pernat A, Buturovi?-Ponikvar J, Svigelj V, et al. Guillain-Barré syndrome treated by membrane plasma exchange and/or immunoadsorption[j]. Ther Apher Dial, 2009, 13(4):310-313.
[23] Dyck P, Tracy J. History, diagnosis, and management of chronic inflammatory demyelinating polyradiculoneuropathy [j]. Mayo Clin Proc, 2018, 93(6): 777-793.
[24] Pham H, Schwartz J. Therapeutic plasma exchange in Guillain-Barre Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy[j]. Presse Med, 2019 , 48(11 Pt 2): 338-346.
[25] Isose S, Mori M, Misawa S, et al. Long-term regular plasmapheresis as a maintenance treatment for chronic inflammatory demyelinating polyneuropathy[j]. J Peripher Nerv Syst
,2010, 15(2):147-149.
[26] Schwartz J, Padmanabhan A, Aqui N，et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the seventh special issue[j]. J Clin Apher, 2016, 31(3): 149-162.
[27] Devaux J, Miura Y, Fukami Y, et al. Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy[j]. Neurology, 2016, 86(9): 800-807.
[28] Dorst J, Ludolph A, Senel M, et al. Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients[j]. J Neurol, 2018, 265(12): 2906-2915.
[29] Gilhus N. Myasthenia Gravis[j]. N Engl J Med, 2016, 375(26):2570-2581.
[30] Guptill J, Sanders D, Evoli A, et al. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts[j]. Muscle Nerve, 2011, 44(1):36-40.
[31] Usmani A, Kwan L, Wahib-Khalil D, et al. Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status [j]. J Clin Apher, 2019, 34(4): 416-422.
[32] Schneider-Gold C, Krenzer M, Klinker E, et al. Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration [j]. Ther Adv Neurol Disord
,2016, 9(4):297-303.
